Cingulate

Cingulate Operating Expenses

The Total Operating Expenses of Cingulate (CING) as of Oct 21, 2026 is 19.94 M USD. In the previous year, Total Operating Expenses was 15.65 M USD — a change of 27.44% (higher).

Operating Expenses

19.94 MUSD

YoY

27.44%

Last updated:

Total Operating Expenses of Cingulate is 2025 19.94 M USD. Total Operating Expenses of Cingulate was 2024 15.65 M USD. It decreases by 27.44% higher compared to the previous year.

The Cingulate Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
11.40 M USD
Jan 1, 2020
7.08 M USD
Jan 1, 2021
20.68 M USD
Jan 1, 2022
17.50 M USD
Jan 1, 2023
22.76 M USD
Jan 1, 2024
15.65 M USD
Jan 1, 2025
19.94 M USD
The Cingulate Operating Expenses history
YEAROperating ExpensesYoY
19.94 MUSD+27.44%
15.65 MUSD-31.26%
22.76 MUSD+30.04%
17.50 MUSD-15.37%
20.68 MUSD+191.91%
7.08 MUSD-37.84%
11.40 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Total Operating Expenses of Cingulate is 19.94 M USD in 2025.

Total Operating Expenses of Cingulate changed from 15.65 M USD to 19.94 M USD, representing a 27.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Cingulate since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cingulate

All Key Metrics — Cingulate